^
    2ms
    MUCINOUS LUNG ADENOCARCINOMA PRESENTING AS A HEMORRHAGIC PLEURAL EFFUSION (CHEST 2024)
    With the presence of the ALK rearrangement, the patient was started on alectinib...The patient subsequently underwent three cycles of carboplatin/pemetrexed, and ultimately transitioned to hospice care and passed away fourteen months after initial diagnosis... Mucinous adenocarcinoma is an uncommon histological subtype of lung adenocarcinoma with a poor prognosis, with patients often presenting at a later disease stage with complications which may include malignant pleural effusions.
    Pleural effusion • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • NKX2-1 (NK2 Homeobox 1) • NAPSA (Napsin A Aspartic Peptidase)
    |
    PD-L1 expression • PD-L1 overexpression • ALK rearrangement
    |
    PD-L1 IHC 22C3 pharmDx • NeoTYPE® Lung Tumor Profile
    |
    carboplatin • Alecensa (alectinib) • pemetrexed
    over2years
    NeoGenomics Inc. announces partnership with Lilly for lung cancer sponsored testing program utilizing the NeoTYPE(R) DNA and RNA assay (NeoGenomics Press Release)
    "NeoGenomics, Inc...announced today that they are partnering with Eli Lilly and Company on a sponsored testing program for eligible patients with metastatic non-small cell lung cancer (NSCLC) at no cost...The Lilly Lung Cancer Sponsored Testing Program will utilize the NeoTYPE® DNA and RNA Assay to provide eligible metastatic NSCLC patients with enhanced access to a targeted genomic test offering that can help physicians and patients make informed treatment decisions. For cases where results are not attainable due to low tissue input or when an invasive biopsy is medically contraindicated, eligible patients are able to instead use InVisionFirst®-Lung Liquid Biopsy at no cost."
    Licensing / partnership
    |
    InVisionFirst®-Lung • NeoTYPE® Lung Tumor Profile
    almost3years
    Necrotizing Pneuomonia to Mucinous Adenocarcinoma (ATS 2022)
    This tumor was Thyroid Transcription Factor-1 negative, which statistically has a poorer prognosis due to its invasive nature compared to its counterpart. Fortunately, based on her PET scan, there is no evidence of metastatic disease and she is planned for a lobectomy.(Figure 1)
    NKX2-1 (NK2 Homeobox 1)
    |
    NeoTYPE® Lung Tumor Profile